0.4985

2.27% -0.0116

Pre-market: .51 0.0115 +2.31%

Elevation Oncology Inc (ELEV)

Overview News Price History Financials Discussions Forecast

Elevation Oncology Inc stock is traded at $0.4985, with a volume of 398.52K. It is down -2.27% in the last 24 hours and down -24.36% over the past month. Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.

Previous Close:

$0.5101

Open:

$0.5041

24h Volume:

398.52K

Relative Volume:

0.19

Market Cap:

$29.52M

Revenue:

Net Income/Loss:

$-41.95M

P/E Ratio:

-0.6006

EPS:

-0.83

Net Cash Flow:

$-38.34M

1W Performance:

-2.43%

1M Performance:

-24.36%

6M Performance:

-18.12%

1Y Performance:

-88.05%

1-Day Range:

$0.4914

$0.53

1-Week Range:

$0.4613

$0.53

52-Week Range:

$0.4613

$5.8299

Elevation Oncology Inc Stock (ELEV) Company Profile

Name

Elevation Oncology Inc

Sector

Healthcare (1169)

Industry

Biotechnology (679)

Phone

(716) 371-1125

Address

101 FEDERAL STREET, BOSTON

Employee

Twitter

Next Earnings Date

2025-03-05

Latest SEC Filings

ELEV's Discussions on Twitter

Compare ELEV with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ELEV Elevation Oncology Inc	0.4985	29.52M	0	-41.95M	-38.34M	-0.83
VRTX Vertex Pharmaceuticals Inc	502.92	129.14B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	680.61	74.41B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	581.21	35.31B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.75	31.30B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	254.57	27.35B	3.32B	-860.46M	-1.04B	-8.32

Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-03-25	Initiated	William Blair	Outperform
May-31-24	Initiated	Piper Sandler	Overweight
May-14-24	Initiated	Stephens	Overweight
Mar-01-24	Initiated	JMP Securities	Mkt Outperform
May-30-23	Upgrade	SVB Securities	Market Perform → Outperform
Dec-23-21	Initiated	H.C. Wainwright	Buy

View All

Elevation Oncology Inc Stock (ELEV) Latest News

Mar 13, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Mar 13, 2025

HC Wainwright Has Optimistic Outlook of ELEV Q1 Earnings - Defense World

Mar 13, 2025

Mar 11, 2025

Elevation Oncology’s (ELEV) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Mar 11, 2025

Mar 10, 2025

H.C. Wainwright maintains Buy on Elevation Oncology stock By Investing.com - Investing.com UK

Mar 10, 2025

Elevation Oncology stock holds $7 target at JMP Securities By Investing.com - Investing.com Canada

Mar 10, 2025

Elevation Oncology’s (ELEV) “Overweight” Rating Reiterated at Stephens - Defense World

Mar 10, 2025

Buy Recommendation for Elevation Oncology: Promising Pipeline and Strong Financial Management - TipRanks

Mar 10, 2025

Elevation Oncology stock holds $7 target at JMP Securities - Investing.com

Mar 10, 2025

Elevation Oncology’s (ELEV) Outperform Rating Reiterated at William Blair - Defense World

Mar 10, 2025

Analysts Issue Forecasts for ELEV FY2029 Earnings - Defense World

Mar 10, 2025

Research Analysts Offer Predictions for ELEV Q2 Earnings - Defense World

Mar 10, 2025

Mar 08, 2025

Elevation Oncology’s Future in Jeopardy: Financing Challenges Threaten Product Development - TipRanks

Mar 08, 2025

Mar 07, 2025

Elevation Oncology Reports 2024 Financial Results and Progress - TipRanks

Mar 07, 2025

Strategic Advancements and Financial Stability Drive Buy Rating for Elevation Oncology - TipRanks

Mar 07, 2025

Mar 06, 2025

Elevation Oncology Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 06, 2025

Elevation Oncology reports Q4 EPS (18c), consensus (22c) - TipRanks

Mar 06, 2025

Elevation Oncology, Inc. SEC 10-K Report - TradingView

Mar 06, 2025

Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements - Marketscreener.com

Mar 06, 2025

Elevation Oncology : Corporate OverviewMarch 2025 -March 06, 2025 at 04:34 pm EST - Marketscreener.com

Mar 06, 2025

Can Elevation Oncology's $93M War Chest Transform Cancer Treatment? Key Pipeline Updates - StockTitan

Mar 06, 2025